Table 1.
Canonical pathways associated with genes preferentially dysregulated in individual Mef2 shRNA treatments
Ingenuity Pathway Analysis® of canonical pathways preferentially dysregulated by Mef2 shRNA treatment was conducted. The analyzed gene set represents genes that were only statistically dysregulated in knockdown of a single MEF2 factor. The top five most significantly regulated canonical pathways are presented with the number of genes dysregulated in relation to the accepted number of genes associated with each canonical pathway (ratio). TCA, tricarboxylic acid.
| Canonical pathway | p | Ratio |
|---|---|---|
| MEF2A | ||
| Germ cell-Sertoli cell junction signaling | 1.07E−08 | 50:160 (0.312) |
| Molecular mechanisms of cancer | 1.81E−08 | 90:365 (0.247) |
| 14-3-3-mediated signaling | 1.98E−07 | 38:117 (0.325) |
| Protein ubiquitination pathway | 2.13E−07 | 66:255 (0.259) |
| Death receptor pathway | 3.13E−07 | 32:92 (0.348) |
| MEF2C | ||
| Mitochondrial dysfunction | 1.96E−07 | 13:171 (0.076) |
| TCA cycle II (eukaryotic) | 2.17E−05 | 4:23 (0.174) |
| Fatty acid oxidation III (unsaturated, odd number) | 2.40E−05 | 2:3 (0.667) |
| Oxidative phosphorylation | 3.05E−05 | 8:109 (0.073) |
| Methylmalonyl pathway | 3.67E−05 | 2:4 (0.50) |
| MEF2D | ||
| HIPPO signaling | 2.08E−04 | 11:86 (0.128) |
| PI3K signaling in B lymphocytes | 5.78E−04 | 13:128 (0.102) |
| Neuregulin signaling | 1.03E−03 | 10:88 (0.114) |
| Proline degradation | 1.23E−03 | 2:2 (1.00) |
| Fc receptor-mediated phagocytosis in macrophages and monocytes | 1.57E−03 | 10:93 (0.108) |
| All MEF2 | ||
| Cell cycle control of chromosomal replication | 0.000000499 | 8:27 (0.296) |
| Hepatic fibrosis/hepatic stellate cell activation | 4.47E−05 | 17:198 (0.086) |
| Antiproliferative role of TOB in T-cell signaling | 6.70E−05 | 6:26 (0.231) |
| Cell cycle: G1/S checkpoint regulation | 6.94E−05 | 9:64 (0.141) |
| Factors promoting cardiogenesis in vertebrates | 2.52E−04 | 10:92 (0.109) |